RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can radiation plus immunotherapy shrink recurrent head and neck tumors before surgery?
Disease control Recruiting nowThis study is testing whether combining radiation therapy (proton or X-ray) with the immunotherapy drug pembrolizumab before surgery is safe and effective for people with recurrent head and neck cancer. The trial has two phases: the first checks safety and the right dose, and the…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Could immunotherapy replace Chemo-Radiation after head and neck cancer surgery?
Disease control Recruiting nowThis phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) alone can work better than the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 w…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
New combo attack: immunotherapy plus chemo before surgery for head and neck cancer
Disease control Recruiting nowThis phase 2 trial tests whether giving the immunotherapy drug pembrolizumab along with chemotherapy before surgery, followed by pembrolizumab alone for about a year after surgery, can improve outcomes for people with recurrent head and neck cancer. The study aims to see if this …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New triple-drug cocktail takes on hard-to-treat head and neck cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immuno…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to shrink head and neck tumors that resist standard treatment
Disease control Recruiting nowThis study tests whether adding an experimental drug called ficerafusp alfa to the immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1-positive head and neck cancer that has spread or returned. About 650 adults will be randomly assig…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail aims to extend life in Tough-to-Treat head and neck cancer
Disease control Recruiting nowThis Phase 3 trial is testing whether adding ficlatuzumab to the standard drug cetuximab helps people with recurrent or metastatic HPV-negative head and neck cancer live longer. About 410 adults will be randomly assigned to receive either the combination or a placebo plus cetuxim…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Can a targeted drug shrink tumors when immunotherapy fails?
Disease control Recruiting nowThis phase 2 trial is testing the drug cetuximab by itself in people with head and neck cancer that has come back or spread. Participants have already tried immunotherapy (PD-1 inhibitors) and it stopped working or caused side effects. The study will measure how many patients see…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Personalized vaccine takes on head and neck cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New combo therapy aims to extend life in hard-to-treat head and neck cancer
Disease control Recruiting nowThis phase 3 trial tests whether giving re-radiation with chemotherapy followed by the immunotherapy drug pembrolizumab can help people with recurrent head and neck cancer live longer compared to standard pembrolizumab alone or with chemotherapy. The study includes 214 adults who…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a common cholesterol drug boost immunotherapy against head and neck cancer?
Disease control Recruiting nowThis phase II trial tests whether adding lovastatin, a common cholesterol-lowering drug, to the immunotherapy pembrolizumab can help shrink tumors in people with head and neck cancer that has returned or spread. The study will enroll 28 adults whose tumors express PD-L1. Research…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Light-Activated drug combo takes on recurrent head and neck cancer in major trial
Disease control Recruiting nowThis phase 3 trial tests whether a new treatment called ASP-1929 photoimmunotherapy (a light-activated drug) combined with the immunotherapy pembrolizumab works better than standard care for people with recurrent head and neck cancer that hasn't spread to other parts of the body.…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Rakuten Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Glow-in-the-Dark dye could help surgeons see hidden cancer during surgery
Disease control Recruiting nowThis early-stage trial is testing whether a combination of two imaging agents can help surgeons better detect and remove head and neck cancer. One agent uses a radioactive label for pre-surgery scans, and the other uses a fluorescent dye that makes cancer cells glow during surger…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New imaging agent aims to spot hidden cancer in neck lymph nodes
Diagnosis Recruiting nowThis early-stage trial tests whether a radioactive imaging agent called 111In-panitumumab can help find cancer that has spread to lymph nodes in people with head and neck cancer. The agent binds to a protein common on cancer cells and lights up on a special scan. About 30 partici…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
Cancer patients may soon get immunotherapy at home instead of the clinic
Symptom relief Recruiting nowThis study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Blood test may predict head and neck cancer progression
Knowledge-focused Recruiting nowThis observational study is testing a new blood test that uses a microfluidic chip to detect cancer cells and immune cells in 30 patients with recurrent or metastatic head and neck cancer. The goal is to see if these blood markers can predict how long patients live without their …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC